尼妥珠单抗联合化疗治疗转移性鼻咽癌的研究

Study of Nimotuzumab Combined with Chemotherapy Treatment for Metastatic Nasopharyngeal Carcinoma

摘要: 目的观察尼妥珠单抗联合吉西他滨治疗晚期转移性鼻咽癌的近期疗效和不良反应。方法 13例既往接受过多方案化疗的晚期转移性鼻咽癌患者，接受尼妥珠单抗每周200 mg，静脉滴注；吉西他滨1 000 mg/m2，静脉滴注，d1、d8，每3周重复，每2周期评价疗效。结果全组13例中，CR 2例(15.2%），PR 6例(46.2%），CR+PR 61.5%，1年生存率76.9%。不良反应主要为Ⅰ~Ⅱ度骨髓抑制。结论尼妥珠单抗联合吉西他滨方案治疗晚期转移性鼻咽癌的近期疗效确切，耐受性好。

Abstract: Objective To evaluate the outcome and side-effect of nimotuzumab combined with gemcitabine chemotherapy for metastatic nasopharyngeal carcinoma. Methods Thirteen cases of metastatic nasopharyngeal carcinoma were included in this study.All patients received nimotuzumab (200 mg/w)combined with gemcitabine(1 000 mg/m2，d1，d8)regimen therapy， 21 days was one cycle.Their clinical response was assessed after 2 cycles of chemotherapy. Results There were 2 CR cases(15.2%)，6 PR cases(46.2%)，the total response rate(CR+PR)was 61.5%；1 year survival rate was 76.9%.Drug related toxic effect was I-Ⅱ grand bone narrow depression. Conclusion Nimotuzumab combined with gemcitabine has a better short-term efficacy in the treatment of patients with metastatic nasopharyngeal carcinoma，and the toxicities are acceptable.